Galantamine — Membership Pricing

Other medications in Neurological

• Galcanezumab
• Glatiramer
• Interferon Beta-1a
• Interferon Beta-1b
• Lacosamide
• Lasmiditan
• Meclizine
• Memantine

About Galantamine

Galantamine is a medication prescribed to help manage mild to moderate Alzheimer's disease symptoms, potentially improving cognitive function. At TheDrugClub, we understand the importance of affordable access to vital medications like galantamine. Our membership program is designed to help you save on your prescriptions, making your healthcare journey a little easier.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Galantamine is approved for (FDA label)

Galantamine tablets are indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. Galantamine tablets are a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: July 2, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Galantamine (FDA label)

Galantamine tablets USP contain 4 mg, 8 mg, and 12 mg galantamine as 5.126 mg, 10.253 mg, and 15.379 mg of galantamine hydrobromide, respectively. Galantamine tablets USP are available in the following strengths: 4 mg off-white, circular, biconvex, film-coated tablets debossed with ‘F’ on one side and ‘49’ on the other side 8 mg pink, circular, biconvex, film-coated tablets debossed with ‘F’ on one side and ‘50’ on the other side 12 mg orange-brown, circular, biconvex, film-coated tablets debossed with ‘F’ on one side and ‘51’ on the other side Tablets – 4 mg, 8 mg, 12 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 261889d3-41c8-4655-98f7-41317778e7a1. SPL document ID: 0ff532b0-a51d-4321-9926-f41ab26be5ee. Label effective date: July 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Galantamine (FDA label)

Serious adverse reactions are discussed in more detail in the following sections of the labeling: Serious skin reactions [see Warnings and Precautions (5.1) ] Cardiovascular Conditions [see Warnings and Precautions (5.3) ] Gastrointestinal Conditions [see Warnings and Precautions (5.4) ] Genitourinary Conditions [see Warnings and Precautions (5.5) ] Neurological Conditions [see Warnings and Precautions (5.6) ] Pulmonary Conditions [see Warnings and Precautions (5.7) ] Deaths in subjects with mild cognitive impairment (MCI) [see Warnings and Precautions (5.8) ] The most common adverse reactions (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 261889d3-41c8-4655-98f7-41317778e7a1. SPL document ID: 0ff532b0-a51d-4321-9926-f41ab26be5ee. Label effective date: July 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Galantamine (FDA label)

Galantamine tablets are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation. Known hypersensitivity to galantamine hydrobromide or any excipients

Source: FDA prescribing information (DailyMed). Set ID: 261889d3-41c8-4655-98f7-41317778e7a1. SPL document ID: 0ff532b0-a51d-4321-9926-f41ab26be5ee. Label effective date: July 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Galantamine (FDA label)

Serious skin reactions: discontinue at first appearance of skin rash (5.1) All patients should be considered at risk for adverse effects on cardiac conduction, including bradycardia and AV block, due to vagotonic effects on sinoatrial and atrioventricular nodes (5.3) Active or occult gastrointestinal bleeding: monitor, especially those with an increased risk for developing ulcers (5.4) Cholinomimetics may cause bladder outflow obstruction (5.5) Monitor for respiratory adverse events in patients with a history of severe asthma or obstructive pulmonary disease (5.7) 5.1 Serious Skin Reactions Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine. Inform patients and caregivers that the use of galantamine should be discontinued at the first appearance of a skin rash, unless the rash is clearly not drug-related.

Source: FDA prescribing information (DailyMed). Set ID: 261889d3-41c8-4655-98f7-41317778e7a1. SPL document ID: 0ff532b0-a51d-4321-9926-f41ab26be5ee. Label effective date: July 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Galantamine (FDA label)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) 7.1 Use with Anticholinergics Galantamine has the potential to interfere with the activity of anticholinergic medications [see Clinical Pharmacology (12.3) ] . 7.2 Use With Cholinomimetics and Other Cholinesterase Inhibitors A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol [see Clinical Pharmacology (12.3) ] .

Source: FDA prescribing information (DailyMed). Set ID: 261889d3-41c8-4655-98f7-41317778e7a1. SPL document ID: 0ff532b0-a51d-4321-9926-f41ab26be5ee. Label effective date: July 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.